Literature DB >> 24877660

Effect of whole soy and purified isoflavone daidzein on renal function--a 6-month randomized controlled trial in equol-producing postmenopausal women with prehypertension.

Zhao-min Liu1, Suzanne C Ho2, Yu-ming Chen3, Nelson Tang4, Jean Woo5.   

Abstract

OBJECTIVES: The aim of the study was to examine the long-term effect of commonly used whole soy foods (soy flour) and purified daidzein (one major isoflavone and the precursor of equol) on renal function among prehypertensive postmenopausal women who are also equol producers, a population most likely to benefit from soy intervention. DESIGN AND METHODS: This was a 6-month double-blind, randomized, placebo-controlled trial. Two hundred seventy eligible Chinese women were randomized to either one of the three treatments: 40 g soy flour (whole soy group), 40 g low-fat milk powder + 63 mg daidzein (daidzein group) or 40 g low-fat milk powder (placebo group) daily each for 6 months. Fasting blood and 24-h urine samples were collected at the beginning and end of trial. Serum creatinine, cystatin C, urea, angiotensin-converting enzyme, minerals and 24-h urinary creatinine and minerals were analyzed. Estimated glomerular filtration rate (eGFR) was calculated with the Cockcroft-Gault and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations.
RESULTS: Two hundred fifty-three subjects completed the study according to the protocol. Urinary isoflavones indicated good compliance of participants. No significant changes were observed in most of renal parameters, however, there was a less decrease in eGFRcockcroft in 6-month change (p=0.044) and %change (p=0.031) with whole soy intake relative to milk placebo. Subgroup analysis among women with lowered renal function suggested whole soy consumption tended to improve markers of renal function relative to control.
CONCLUSIONS: Six-month consumption of whole soy tended to have a modest improvement of renal function in prehypertensive postmenopausal women with lowered renal function. Future trials in subjects with more declined renal function are necessary. TRIAL REGISTRATION: The trial was registered in ClinicalTrials.gov with identifier of NCT01270737. (URL: http://clinicaltrials.gov/ct2/show/NCT01270737).
Copyright © 2014 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Daidzein; Equol producers; Prehypertension; Renal function; Whole soy

Mesh:

Substances:

Year:  2014        PMID: 24877660     DOI: 10.1016/j.clinbiochem.2014.05.054

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  6 in total

Review 1.  Soy-based renoprotection.

Authors:  Nancy J McGraw; Elaine S Krul; Elizabeth Grunz-Borgmann; Alan R Parrish
Journal:  World J Nephrol       Date:  2016-05-06

2.  Probiotic Soy Milk Consumption and Renal Function Among Type 2 Diabetic Patients with Nephropathy: a Randomized Controlled Clinical Trial.

Authors:  Maryam Miraghajani; Nafiseh Zaghian; Abolfazl Dehkohneh; Maryam Mirlohi; Reza Ghiasvand
Journal:  Probiotics Antimicrob Proteins       Date:  2019-03       Impact factor: 4.609

Review 3.  Current Perspectives on the Beneficial Effects of Soybean Isoflavones and Their Metabolites for Humans.

Authors:  Il-Sup Kim
Journal:  Antioxidants (Basel)       Date:  2021-06-30

4.  Ameliorative Effect of Daidzein on Cisplatin-Induced Nephrotoxicity in Mice via Modulation of Inflammation, Oxidative Stress, and Cell Death.

Authors:  Hongzhou Meng; Guanghou Fu; Jie Shen; Kezhen Shen; Zhijie Xu; Yiming Wang; Baiye Jin; Hao Pan
Journal:  Oxid Med Cell Longev       Date:  2017-08-02       Impact factor: 6.543

5.  Targeting Alzheimer's disease with multimodal polypeptide-based nanoconjugates.

Authors:  A Duro-Castano; C Borrás; V Herranz-Pérez; M C Blanco-Gandía; I Conejos-Sánchez; A Armiñán; C Mas-Bargues; M Inglés; J Miñarro; M Rodríguez-Arias; J M García-Verdugo; J Viña; M J Vicent
Journal:  Sci Adv       Date:  2021-03-26       Impact factor: 14.136

Review 6.  Therapeutic Potential of Isoflavones with an Emphasis on Daidzein.

Authors:  Mohammed M Alshehri; Javad Sharifi-Rad; Jesús Herrera-Bravo; Evelyn L Jara; Luis A Salazar; Dorota Kregiel; Yadav Uprety; Muhammad Akram; Mehwish Iqbal; Miquel Martorell; Margalida Torrens-Mas; Daniel Gabriel Pons; Sevgi Durna Daştan; Natália Cruz-Martins; Fethi Ahmet Ozdemir; Manoj Kumar; William C Cho
Journal:  Oxid Med Cell Longev       Date:  2021-09-09       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.